Biomarkers used for the diagnosis and prognostic in systemic lupus erythematosus
DOI:
https://doi.org/10.56294/saludcyt2023422Keywords:
Systemic Lupus Erythematosus, Antibodies, Biomarkers, Diagnosis, PrognosisAbstract
Introduction: Systemic Lupus Erythematosus or also called SLE is an autoimmune and chronic pathology where there is a dysregulation of the immune system causing the presence of antibodies to attack the body itself. Its symptomatology is classified as type I and II therefore, it is associated with risk factors such as environmental, genetic, and hormonal. This disease is mostly suffered by women of childbearing age between 15 and 45 years, however it is less frequent in children and men.
Objective: to identify the biomarkers that help the diagnosis and prognostic in SLE, describe the classification criteria of SLE and immunological methods for its detection.
Methods: a descriptive research was carried out by searching information about biomarkers used for diagnosis and prognostic in systemic lupus erythematosus through databases such as: Google Scholar, Pubmed, Elsevier, Scielo, Redalyc during the period 2015-2023. The sources consulted were a total of 35 using keywords such as systemic lupus erythematosus, biomarkers, antibodies using in the diagnosis of systemic lupus erythematosus.
Results: it was established that for the diagnosis of SLE biomarkers of early detection, confirmation, activity, nonspecific and other biomarkers that are associated to this pathology. While for prognosis, confirmation biomarkers are useful when a patient has been diagnosed with SLE.
Conclusions: the main biomarkers used in the diagnosis and prognostic of SLE are ANA, anti-dsDNA, anti-SM, anti-RNP, anti-Pribosomal, anti-Ro/SSA and there are also the molecular biomarkers miR-196 and miR146, likewise, criteria such as EULAR/ACR-2019 are used in diagnostic support
References
1. Rubio ER, Emperiale V, Ruiz PP, Castañeda NG. Lupus eritematoso sistémico (I). Medicine - Programa de Formación Médica Continuada Acreditado. abril de 2021;13(31):1739-50. https://doi.org/10.1016/j.med.2021.04.001
2. Tsokos GC. Autoimmunity and organ damage in systemic lupus erythematosus. Nat Immunol. 4 de junio de 2020;21(6):605-14.
3. Diamond B, Lipsky PE. CAPÍTULO 355: Autoinmunidad y enfermedades autoinmunitarias. https://accessmedicina.mhmedical.com/content.aspx?bookid=3118§ionid=268882104
4. Pisetsky DS, Clowse MEB, Criscione-Schreiber LG, Rogers JL. A Novel System to Categorize the Symptoms of Systemic Lupus Erythematosus. Arthritis Care Res (Hoboken). 2019;71(6):735-41. https://doi.org/10.1002/acr.23794
5. Tian J, Zhang D, Yao X, Huang Y, Lu Q. Global epidemiology of systemic lupus erythematosus: A comprehensive systematic analysis and modelling study. Ann Rheum Dis. 2022;351-6.
6. Barber MRW, Drenkard C, Falasinnu T, Hoi A, Mak A, Kow NY, et al. Global epidemiology of systemic lupus erythematosus. Nat Rev Rheumatol. 2021;17(9):515-32.
7. Diario Salud. EL LUPUS UNA ENFERMEDAD SILENCIOSA QUE CAUSA MUCHO DAÑO. https://diariosalud.com.ec/2022/05/09/el-lupus-una-enfermedad-silenciosa-que-causa-mucho-dano/. 2022.
8. Kokuina Elena. Autoanticuerpos como biomarcadores de actividad de la enfermedad del lupus eritematoso sistémico. 2014. http://scielo.sld.cu/scielo.php?script=sci_arttext&pid=S0034-75232014000200009
9. Morgado PJB. ARTICLE IN PRESS FR-Criterios de clasificación 2019 del lupus RF-2019 Classification Criteria for Systemic Lupus Erythematosus. 2021; 113:3-5. https://www.actasdermo.org/es-fr-criterios-clasificacion-2019-del-lupus-avance-S0001731021003720
10. Pisetsky DS. Evolving story of autoantibodies in systemic lupus erythematosus. J Autoimmun. junio de 2020; 110:102356. https://doi.org/10.1016/j.jaut.2019.102356
11. NIH. Biomarkers [Internet]. [citado 11 de abril de 2023]. Disponible en: https://www.niehs.nih.gov/health/topics/science/biomarkers/index.cfm
12. González LA, Ugarte-Gil MF, Alarcón GS. Systemic lupus erythematosus: The search for the ideal biomarker. Vol. 30, Lupus. SAGE Publications Ltd; 2021. p. 181-203.
13. Mendez-Rayo T, Ochoa-Zárate L, Posso-Osorio I, Ortiz E, Naranjo-Escobar J, Tobón GJ. Interpretation of autoantibodies in rheumatological diseases. Vol. 25, Revista Colombiana de Reumatologia. Asociacion Colombiana de Reumatologia; 2018. p. 112-25.
14. Lazar S, Kahlenberg JM. Annual Review of Medicine Systemic Lupus Erythematosus: New Diagnostic and Therapeutic Approaches. 2022. https://doi.org/10.1146/annurev-med-043021-
15. Alcántara H, González M, Cruz M, Silva R, Vilchis Landeros L, Mayoral PC, et al. Comité Editorial: González Andrade Anticuerpos antinucleares por inmunofluorescencia indirecta. Antinuclear antibodies by indirect immunofluorescence. MENSAJE BIOQUÍMICO. Vol. 46, Mens. Bioquím. 2022. http://biosensor.facmed.unam.mx/tab/wp-content/uploads/2022/06/6-Perez-Campos.pdf
16. Alarcón I, Aparicio MaB, García José. APORTACIÓN DEL LABORATORIO CLÍNICO EN EL ESTUDIO DEL LUPUS ERITEMATOSO SISTÉMICO. SEQC. 2016. https://www.seqc.es/download/tema/13/4407/62065/902068/cms/tema-2-aportacion-del-laboratorio-clinico-en-el-estudio-del-lupus-eritematoso-sistemico.pdf/
17. Vázquez Castillo TV, Solís Martínez RA. Frecuencia de patrones de anticuerpos antinucleares en pacientes con sospecha de enfermedades sistématicas reumáticas autoinmunes. Horizonte Sanitario. 23 de septiembre de 2020;19(3):385-92.
18. Juárez-Dobjanschi C, Ferrándiz-Pulido C, Marín-Sánchez A, García-Patos Briones V. Role of autoantibodies in the diagnosis of systemic autoimmune rheumatic diseases with skin involvement. Antinuclear antibodies and extractable nuclear antigens. (Part 1). Piel. 1 de marzo de 2015;30(3):169-80.
19. Tenesaca J, Pasato M. FRECUENCIA DE PATRONES DE ANTICUERPOS ANTINUCLEARES ANA MEDIANTE INMUNOFLUORESCENCIA INDIRECTA Y SU RELACIÓN CON EL DESARROLLO DE ENFERMEDADES AUTOINMUNES EN PACIENTES ATENDIDOS EN EL HOSPITAL VICENTE CORRAL MOSCOSO. ENERO 2019 - DICIEMBRE 2020. [Ecuador]: Universidad de Cuenca; 2023.
20. Rosales C. BETA 2 MICROGLOBULINA, 25 OH VITAMINA D Y FERRITINA CON LA REACTIVACION CLINICA DE LUPUS ERITEMATOSO SISTEMICO Y NEFROPATIA LUPICA. [La Paz]: Universidad Mayor de San Andres; 2019.
21. Pedano V, Pascual C, Silvera É, Vaca A. CONCORDANCIA Y EXACTITUD DIAGNÓSTICA ENTRE INMUNOFLUORESCENCIA INDIRECTA Y ENZIMOINMUNOENSAYO PARA EL CRIBADO DE ANTICUERPOS ANTI-NUCLEARES. Argentina; 2019.
22. Ministerio de Salud Pública. Guia-lupus-eritematoso. Quito; 2013. https://www.salud.gob.ec/wp-content/uploads/2016/09/Guia-lupus-eritematoso.pdf
23. Amengual J, Mozo L, Rodriguez C. Protocolos de diagnóstico inmunológico en enfermedades autoinmunes. SOCIEDAD ESPAÑOLA DE INMUNOLOGÍA GRUPO ESPAÑOL DE AUTOINMUNIDAD (GEAI); 2015. https://atlasautoinmunidad.org/wp-content/uploads/2018/06/Protocolos-de-Diagn%C3%B3stico-Autoinmunidad-GEAI-1.pdf
24. Vancevska A, Nikolic A, Bonaci-Nikolic B, Skiljevic D, Radojkovic D. Assessment of Deoxyribonuclease Activity in Serum Samples of Patients With Systemic Lupus Erythematosus: Fluorescence-Based Method Versus ELISA. J Clin Lab Anal. noviembre de 2016;30(6):797-803.
25. O. CB, G. FS, M. CR. LABORATORIO DE INMUNOLOGÍA EN LA PRÁCTICA CLÍNICA. Revista Médica Clínica Las Condes. noviembre de 2015;26(6):764-75.
26. Dolores M, Mesonero A. TESIS DOCTORAL LUPUS ERITEMATOSO SISTÉMICO. EPIDEMIOLOGÍA Y PRESENTACIÓN CLÍNICA EN EL NOROESTE DE ESPAÑA. 2017.
27. Deska Pagana K, Pagana TJ, Noel Pagana T. Mosby’s Diagnostic and Laboratory Test Reference. Mosby’s Diagnostic and Laboratory Test Reference. 2019.
28. Aringer M. Inflammatory markers in systemic lupus erythematosus. J Autoimmun. junio de 2020;110:102374. https://doi.org/10.1016/j.jaut.2019.102374
29. García M. Biomarcadores no invasivos de actividad en lupus eritematoso sistémico. Universidad de Valladolid; 2015. https://uvadoc.uva.es/bitstream/handle/10324/18033/Tesis1073-160720.pdf?sequence=1&isAllowed=y
30. Ortego N. Cuadernos-Autoinmunidad-Año-12-num-2. Asociación Andaluza de Enfermedades Autoinmunes (AADEA), con periodicidad cuatrimestral y carácter multidisciplinario. 2019;2. https://aadea.es/wp-content/uploads/2019/07/Cuadernos-Autoinmunidad-A%C3%B1o-12-num-2.pdf
31. Mendez-Rayo T, Ochoa-Zárate L, Posso-Osorio I, Ortiz E, Naranjo-Escobar J, Tobón GJ. Interpretation of autoantibodies in rheumatological diseases. Vol. 25, Revista Colombiana de Reumatologia. Asociacion Colombiana de Reumatologia; 2018. p. 112-25.
32. Kokuina E, Estévez M, Toro D, Rojas G, Labrada AO, Bruzón S, et al. Identification of relapse aerological predictors in patients with systemic lupus erythematous: a prospective study of 12 months. Vol. 55, Revista Cubana de Medicina. 2016. https://www.medigraphic.com/cgi-bin/new/resumenI.cgi?IDARTICULO=65336
33. Tan G, Baby B, Zhou Y, Wu T. Emerging Molecular Markers Towards Potential Diagnostic Panels for Lupus. Front Immunol. 13 de enero de 2022;12.
34. Motawi TK, Mohsen DA, El-Maraghy SA, Kortam MA. MicroRNA-21, microRNA-181a and microRNA-196a as potential biomarkers in adult Egyptian patients with systemic lupus erythematosus. Chem Biol Interact. diciembre de 2016;260:110-6.
35. León C, Rojas R, Fuentes F, Hernandez A. Las citopenias en el lupus eritematoso sistémico. Revista Clínica de la Escuela de Medicina UCR-HSJD. 2019
Published
Issue
Section
License
Copyright (c) 2023 Karen Michelle Jaramillo Sancho , Gabriela Paola Valenzuela Sánchez (Author)
This work is licensed under a Creative Commons Attribution 4.0 International License.
The article is distributed under the Creative Commons Attribution 4.0 License. Unless otherwise stated, associated published material is distributed under the same licence.
